Recent News

• 09.16.2025 - Danielle Brill
• 09.16.2025 - Cory Kasimov
• 09.16.2025 - Neurocrine Biosciences to Present New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder at 38th Annual Psych Congress 2025
• 09.16.2025 - Neurocrine Biosciences to Present New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder at 38th Annual Psych Congress 2025
• 08.26.2025 - Neurocrine Biosciences to Present at Upcoming Investor Conferences in September
• 08.26.2025 - Voyager to Present at Upcoming Investor Conferences
• 08.06.2025 - Neurocrine Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference
• 08.06.2025 - Voyager Reports Second Quarter 2025 Financial and Operating Results
• 07.30.2025 - Neurocrine Biosciences Reports Second Quarter 2025 Financial Results
• 07.16.2025 - Voyager Adds Fourth Wholly-Owned Alzheimer’s Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach

Recent Filings

• 09.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.11.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.07.2025 - 144 Report of proposed sale of securities
• 08.07.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.30.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 07.30.2025 - 8-K Current report
• 07.30.2025 - EX-99.1 EX-99.1